• Publications
  • Influence
Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience.
TLDR
Findings show that the radiation of the short-range (maximal 10 microns) Auger electrons originating from the cells of the proximal tubules is not harmful for the renal function. Expand
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
TLDR
There is a benefit in overall survival of several years from the time of diagnosis in patients treated with [(177)Lu-DOTA(0),Tyr(3)]octreotate, and if more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable GEPNETs. Expand
Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours
TLDR
Quality of life improves significantly after treatment with [177Lu-DOTA0,Tyr3]octreotate and the role in somatostatin receptor expressing non-GEP tumours, like metastasised paraganglioma/pheochromocytoma and non-radioiodine-avid differentiated thyroid carcinoma might become more important. Expand
Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives
TLDR
A review on the basic science, historical background and current knowledge of somatostatin receptor subtypes and their expression in neuroendocrine tumours and the use of radiolabelled analogues for somatstatin receptor-mediated therapy is presented. Expand
Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention
TLDR
An overview of renal handling of radiolabeled peptides and resulting nephrotoxicity is presented, and strategies to reduce neph rotoxicity are discussed. Expand
Peptide receptor imaging and therapy.
TLDR
Patients with somatostatin receptor-positive neuroendocrine tumors, such as pituitary tumors, endocrine pancreatic tumors, carcinoids, gastrinomas, and paragangliomas, or other diseases in which som atostatin receptors may also be expressed are reviewed, to show that peptide receptor radionuclides with appropriate particle ranges may become a new treatment modality. Expand
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
TLDR
The effects of 177Lu-octreotate therapy were studied in 35 patients with neuroendocrine gastro-entero-pancreatic (GEP) tumours who underwent follow-up for 3–6 months after receiving their final dose and advocate its use in patients with GEP tumours without waiting for tumour progression. Expand
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
TLDR
After PRRT with [177Lu-DOTA0,Tyr3]octreotate, the radioactivity concentration in the bone marrow is identical to that in the blood; there is no significant binding of the radiopharmaceutical to bone marrow precursor stem cells; and there is considerable variation in bone marrow absorbed dose between patients. Expand
[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.
TLDR
In comparison with the radionuclide-coupled somatostatin analogues that are currently available for som atostatin receptor-mediated radiotherapy, 177Lu-octreotate potentially represents an important improvement. Expand
Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine
TLDR
It is concluded that co-infusion of Lys75 or LysArg results in a significant inhibition of renal radioactivity in PRRT, allowing higher treatment doses and thus resulting in higher tumour radiation doses. Expand
...
1
2
3
4
5
...